|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||12.60 - 12.80|
|52 Week Range||7.21 - 19.87|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus.
India's vast population will have access from today to the Australian developed anti-COVID nasal spray Viraleze™ following its registration in the country.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...